Aims: Diet-derived short chain fatty acids (SCFAs) improve glucose homeostasis in vivo, but the role of individual SCFAs and their mechanisms of action have not been defined. This study evaluated the effects of increasing colonic delivery of the SCFA propionate on β-cell function in humans and the direct effects of propionate on isolated human islets in vitro.
| INTRODUCTION
Diets containing high amounts of indigestible components such as complex carbohydrates and fibre increase satiety, promote weight loss and improve glucose homeostasis in both animals and humans. 1, 2 It is thought that the key event in transducing the beneficial effects of these indigestible foods is through their fermentation by colonic anaerobic bacteria to generate the short chain fatty acids (SCFAs) acetate, propionate and butyrate. The colon contributes substantially to circulating acetate levels in man, with peak concentrations of~200 μM observed after caecal delivery of the fermentable disaccharide lactulose 3 or oral delivery of SCFAs. 4 In contrast, circulating levels of propionate and butyrate are reported to be approximately 10-fold lower. 2 It is now apparent that these SCFAs can exert their effects through activation of the G-protein coupled receptors (GPCRs) FFAR2 and FFAR3, 1, 2, 5 either locally in the colon and/or following their absorption into the systemic circulation. FFAR3 is coupled intracellularly to inhibitory pathways via Gαi whilst FFAR2 is coupled to both Gαi and stimulatory signalling via Gαq. 6 FFAR2 is expressed by colonic L-cells and SCFAs can stimulate GLP-1 release from these cells. [7] [8] [9] We have shown that propionate stimulation of GLP-1 and PYY secretion is dependent on FFAR2 activation 10 and it has been demonstrated that FFAR2 deletion in mice impairs glucose tolerance and reduces glucose-stimulated GLP-1 release. 9 These observations fit with a model in which dietary fibre improves glycaemic control through production of SCFAs in the colon; activation of L-cell FFAR2 and the consequent increased GLP-1 release promotes insulin secretion from β-cells.
However, signalling of SCFAs in tissues distinct from L-cells can also contribute to improved glucose homeostasis. For example, FFAR2
is expressed by adipocytes and the pancreas, 2 implying important roles in lipid and glucose regulation. Consistent with this, SCFAs act directly at adipocytes to inhibit lipolysis, 10 thus reducing levels of adipocytederived long chain non-esterified fatty acids (NEFA) such as palmitate that contribute to glycaemic deterioration. 2, 11 In addition, SCFAs can act directly at islet β-cells to regulate insulin secretion. However, the studies reported to date have largely been performed using mouse islets, which may not appropriately reflect the human situation. [12] [13] [14] They have focused on the direct effects of acetate on β-cells and there is currently no consensus from these studies on whether insulin release is stimulated or inhibited by this SCFA, [12] [13] [14] nor on the role of the other circulating SCFA, propionate. We have recently demonstrated that targeted administration of propionate to the colon, in the form of inulinpropionate ester (IPE), acutely reduces energy intake and ameliorates long-term weight gain in overweight adults. 15 We have now extended our studies to investigate the effects of increasing colonic propionate for 24 weeks on glucose homeostasis in humans, with a focus on acute circulating NEFA and insulin levels following a mixed calorie meal test. We have also analysed the effects of propionate on β-cell function in vivo using the oral disposition index.
We have complemented the assessment of in vivo delivery of propionate with characterization of its direct effects in vitro to regulate insulin secretion from human islets and protect them against apoptosis. Our data demonstrate that long-term colonic propionate delivery significantly improves β-cell function, as evidenced by increased circulating insulin without any changes in insulin sensitivity, an effect that is not secondary to increased GLP-1 levels. in vitro experiments with human islets indicate that propionate acts directly to reversibly stimulate insulin secretion through a protein kinase C-dependent pathway and protect islets from apoptosis induced by cytokines and the NEFA palmitate.
| MATERIALS AND METHODS

| Materials
Materials used in the study include: culture media and supplements and general laboratory chemicals from Sigma-Aldrich (Dorset, UK);
Alexa-fluor secondary antibodies from GE Healthcare Life Sciences 
| Colonic propionate delivery in vivo
We have developed IPE as a vehicle to efficiently deliver propionate to the colon. 15 We have previously reported the impact of IPE on appetite regulation and bodyweight maintenance, 16 and here we analyse its effect on glucose homeostasis. 
| Human islets
Human islets were isolated from 22 non-diabetic donors (age: 
| Insulin secretion in vitro
For static incubation assessment of insulin secretion, groups of 5 human islets were incubated for 30 minutes at 37 C in buffer 18 supplemented with agents of interest, after which insulin release was quantified by radioimmunoassay. 19 For perifusion experiments, groups of 50 human islets were perifused with a physiological salt solution 18 and perifusate samples were collected at 2-minute intervals for quantification of secreted insulin. [19] [20] [21] Islet PKC can be selectively down-regulated by maintenance for 20 hours in the presence of 4β phorbol 12-myristate 13-acetate (PMA) 20 ; thus, in some experiments the role of PKC was investigated by perifusing islets that had been treated with PMA to deplete PKC. Sodium propionate was dissolved in the physiological salt solution 18 immediately before experimental use.
| Western blotting
Groups of 200 human islets were lysed and protein was quantified by the BCA method. Fifty micrograms of islet protein extracts were fractionated by denaturing SDS polyacrylamide gel electrophoresis (10% gel, 45 minutes, 200 V), transferred onto 0.2 μm nitrocellulose and probed overnight at room temperature with rabbit anti-FFAR2 antibody (1:500). The membrane was then incubated for 1 hour at room temperature with anti-rabbit HRP-conjugated secondary antibody
(1:10 000) and exposed to X-ray film after addition of ECL substrate.
| Fluorescence immunohistochemistry
Non-pathological human pancreas 5-μm sections were boiled in 0.01 M citric acid buffer (pH 6.0) for 2.5 minutes for antigen retrieval, blocked (0.1% donkey serum in PBS with 0.02% triton X-100, 1 hour, room temperature) and incubated at 4 C overnight with goat anti-FFAR2 (1:50) and guinea pig anti-insulin (1:250) antibodies. Sections were then exposed to Alexa-fluor secondary antibodies (1:250) for 1 hour at room temperature; nuclei were stained with DAPI and images were acquired using a Nikon Eclipse TE2000-U microscope.
| Calcium microfluorimetry
Groups of 100 000 dispersed human islet cells on glass coverslips
were incubated for 15 minutes with 5 μM Fura-2 AM. The coverslips were placed in a steel chamber that was mounted onto a heating platform of an Axiovert 135 inverted microscope. Cells were perifused (1 mL/min) with a physiological salt solution 18 containing test agents.
Real-time changes in [Ca
2+
] i were determined by illuminating cells alternately at 340 and 380 nm, with the emitted light being filtered at 510 nm and recorded with a CCD camera. Data were collected every 3 seconds from multiple cells in a field of view. 
| Cyclic AMP
Groups of 5 human islets were incubated for 1 hour at 37 C in a physiological salt solution containing 20 mM glucose and supplemented with 2 mM IBMX to inhibit phosphodiesterases. Islets were then lysed and cAMP levels were quantified using a cAMP fluorescence assay, according to the manufacturer's instructions. Data were acquired using a PHERAstar FS microplate reader (100 μs delay time, 100 μs integration time, 50 flash read time).
| ATP
Groups of 3 human islets were incubated for 1 hour at 37 C, lysed
and ATP levels were determined by chemiluminescence with the Cell
Titer-Glo assay, according to the manufacturer's instructions. 21 
| Apoptosis
Human islets were pre-cultured in complete CMRL medium in the absence or presence of propionate for 24 hours, and groups of 5 islets were exposed to CMRL with 0.2% albumin supplemented with either 500 μM sodium palmitate or a cytokine cocktail (5U/μL TNFα, 0.5U/ μL IL-1β, 5U/μL IFNγ) in the continued absence or presence of propionate for a further 20 hours. Islet cell apoptosis was determined using the Caspase3/7 Glo assay according to the manufacturer's instructions. 21 Mean luminescence data of each group of islets were normalized to the basal apoptosis levels obtained in the absence of cytokines or sodium palmitate.
| Statistical analyses
Changes in postprandial glucose, insulin, NEFA and GLP-1 levels at week 24 were calculated as differences from presupplementation values. Between-group differences were ana- 
| RESULTS
| Colonic propionate delivery improves β-cell function in vivo
Analysis of AUC 0-30 minutes after the meal test indicated that there was a significant reduction in plasma NEFA levels in subjects who had received the IPE supplement for 24 weeks ( Figure 1A ) and significant reductions in NEFA were also evident over the 120-minute postprandial period ( Figure S1A ). Long-term colonic propionate delivery was also associated with a significant increase in circulating insulin levels in the first 30 minutes following the meal ( Figure 1B) , independent of elevations in the early postprandial glucose levels ( Figure 1C ). There was also a trend for long-term propionate delivery to increase insulin secretion over 120 minutes (P = .08), again without any change in glucose levels ( Figure S1B-C) . Calculation of the Matsuda Index 24 indicated that the change in IS at week 24 did not differ between groups ( Figure 1D ), but the oral disposition index demonstrated that those subjects taking the IPE supplement had improved β-cell function ( Figure 1E ), which was not associated with increases in circulating GLP-1 levels ( Figure 1F , Figure S1D ). We have previously reported that IPE supplementation increases propionate concentrations in the peripheral circulation, 16 suggesting that the observed increase in acute insulin secretion could be a consequence of circulating propionate acting directly at islet β-cells.
| Propionate potentiates dynamic insulin secretion from human islets in vitro.
Static incubation experiments in which human islets were incubated in the presence of 1 mM sodium propionate for 30 minutes indicated that it did not significantly affect insulin secretion, despite the islets showing an appropriate secretory response when glucose levels were increased from 2 to 20 mM and when they were challenged with the muscarinic agonist carbachol, which acts via a Gq-coupled GPCR (Figure 2A) . 
| Human islet β-cells express FFAR2
SCFAs signal through binding to the GPCRs FFAR2 and FFAR3, which show widespread distribution. We have previously detected mRNAs encoding these receptors in human islets, 26 immunoreactivity evident in the exocrine pancreas ( Figure 3B ). ] i in Fura-2-loaded human islet cells, with an effect that was visible within 30 seconds of exposure ( Figure 4A ).
| Stimulatory effects of propionate on insulin secretion from human islets are dependent on protein kinase C activation
The potentiation of insulin secretion by propionate was abolished in islets that had been exposed to the phorbol ester 4β-phorbol 12-myristate 13-acetate (PMA) for 24 hours to down-regulate PKC, while islets that had been treated with the inactive phorbol ester 4α-phorbol 12,13-didecanoate (PDD) responded appropriately to propionate ( Figure 4B ). Potential signalling of propionate through Gαi was also investigated by quantification of cAMP generation in human islets. These experiments indicated that forskolin caused a substantial increase in islet cAMP production, which was significantly reduced by the α 2 adrenergic agonist clonidine, but not by propionate ( Figure 4C ). SCFAs can diffuse through the plasma membrane because of their short carbon skeletons, and it is possible that they potentiate insulin secretion by acting as mitochondrial metabolic substrates. However, measurements of intracellular ATP levels indicated that, while increasing the glucose concentration from 2 to 20 mM resulted in increased ATP, as expected, co-incubation of islets with 100 μM or 1 mM propionate at 20 mM glucose did not result in further increases in ATP production ( Figure 4D ).
| Propionate protects human islets from cytokine-and palmitate-induced apoptosis
In vivo, islets are susceptible to damage by lipolysis-generated fatty acids such as palmitate, and by cytokines that are secreted following islet infiltration by immune cells. The ability of propionate to protect human islets from apoptosis induced by cytotoxic and lipotoxic environments was evaluated by measurement of caspase 3/7 activities in vitro. Human islets exposed for 20 hours to a cytokine cocktail showed elevations in apoptosis, and a significant increase in human islet caspase 3/7 activities was also observed following exposure to .5 mM sodium palmitate ( Figure 5A,B) . Maintenance of islets in the presence of 1 mM propionate did not affect basal apoptosis, but significantly reduced the pro-apoptotic signalling induced by cytokines ( Figure 5A ) and palmitate ( Figure 5B ).
| DISCUSSION
There is compelling evidence that diet-derived SCFAs have beneficial effects on fuel homeostasis, but the focus to date has been largely on SCFA-mediated improvements in insulin sensitivity 2 or on indirect effects of SCFAs to increase β-cell function via elevations in GLP-1 release from L-cells. 1 In the current study we have demonstrated that subjects undergoing mixed calorie meal tests containing 10 g inulinpropionate ester, after a 24-week programme of daily supplementation with 10 g inulin-propionate ester, show significant improvements in acute insulin secretion and β-cell function compared to control subjects receiving inulin alone. The absence of effect on GLP-1 levels in the acute meal tests in the propionate subjects at 24 weeks points to the enhanced β-cell function being a direct effect of propionate, rather than being secondary to propionate-induced elevations in GLP-1. The limited availability of human islets for research means that the studies to date on the role of SCFAs to directly regulate islet function have been carried out largely using mouse models and/or isolated mouse islets.
12-14,27
The earlier islet studies have focused on the effects of acetate, and there are reports that this SCFA inhibits, 12 stimulates 13 or has no secretion implicate signalling distinct from Gi coupling in human islets. This was confirmed by the lack of inhibition of cAMP production by propionate, indicating that it does not mediate its effects via Gi-coupled FFAR3 in human islets. Propionate may also enter the TCA cycle, and could potentially increase insulin secretion through enhancing ATP synthesis. However, quantification of ATP production indicated that it did not enhance the ATP generation stimulated by glucose in human islets. Thus, the most likely mechanism through which propionate potentiates insulin secretion is via Gq-mediated signalling consequent to FFAR2 activation. This is supported by our data indicating that FFAR2 is expressed by β-cells in human pancreas, as it is in mouse pancreas 12, 14 27 and a FFAR2 agonist that preferentially couples via Gq promotes mouse islet β-cell proliferation. 28 Consistent with
SCFAs playing an important role in maintaining β-cell mass, we have In summary, we have demonstrated that increasing colonic propionate improves β-cell function in vivo, and our in vitro observations in human islets indicate that this may occur both via short-term acute effects of propionate to directly stimulate insulin secretion and through its longer-term effects to protect β-cells from apoptotic stimuli. These data support the ingestion of propiogenic dietary fibres to maintain healthy glucose homeostasis, both through the established beneficial effects via elevations in GLP-1 and PYY 16 and by the novel signalling identified here, of direct stimulatory effects of propionate at β-cells.
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